CN103889957A - 制备高纯度孟鲁司特钠盐的方法 - Google Patents

制备高纯度孟鲁司特钠盐的方法 Download PDF

Info

Publication number
CN103889957A
CN103889957A CN201280050929.4A CN201280050929A CN103889957A CN 103889957 A CN103889957 A CN 103889957A CN 201280050929 A CN201280050929 A CN 201280050929A CN 103889957 A CN103889957 A CN 103889957A
Authority
CN
China
Prior art keywords
montelukast sodium
sodium
light source
formula
montelukast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280050929.4A
Other languages
English (en)
Chinese (zh)
Inventor
李仁尚
李锡洙
申铉益
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Chem Ltd
Original Assignee
LG Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Life Sciences Ltd filed Critical LG Life Sciences Ltd
Publication of CN103889957A publication Critical patent/CN103889957A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
CN201280050929.4A 2011-10-17 2012-10-16 制备高纯度孟鲁司特钠盐的方法 Pending CN103889957A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020110106064A KR20130041664A (ko) 2011-10-17 2011-10-17 고순도 몬테루카스트 나트륨 염의 제조 방법
KR10-2011-0106064 2011-10-17
PCT/KR2012/008411 WO2013058511A2 (ko) 2011-10-17 2012-10-16 고순도 몬테루카스트 나트륨 염의 제조 방법

Publications (1)

Publication Number Publication Date
CN103889957A true CN103889957A (zh) 2014-06-25

Family

ID=48141519

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280050929.4A Pending CN103889957A (zh) 2011-10-17 2012-10-16 制备高纯度孟鲁司特钠盐的方法

Country Status (5)

Country Link
JP (1) JP2014530234A (https=)
KR (1) KR20130041664A (https=)
CN (1) CN103889957A (https=)
IN (1) IN2014CN02765A (https=)
WO (1) WO2013058511A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016020321A (ja) * 2014-07-16 2016-02-04 大日本印刷株式会社 モンテルカストまたはその塩の製造方法
US12233055B2 (en) 2020-02-03 2025-02-25 Taro Pharmaceutical Industries Ltd. Topical Montelukast formulations
CA3166799A1 (en) * 2020-02-03 2021-08-12 Vered Rosenberger Topical montelukast formulations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101323589A (zh) * 2008-03-06 2008-12-17 台耀化学股份有限公司 新化合物及孟鲁司特钠的制备方法
WO2009117381A2 (en) * 2008-03-17 2009-09-24 Dr. Reddy's Laboratories Ltd. Preparation of montelukast and its salts
CN101679268A (zh) * 2007-05-02 2010-03-24 波尔法玛制药工厂股份公司 制备1-(((1(r)-(3-(2-(7-氯-2-喹啉基)-乙烯基)苯基)-3-(2-(1-羟基-1-甲基乙基)苯基)丙基)硫烷基)甲基)环丙乙酸的钠盐的方法
US20100152453A1 (en) * 2006-10-24 2010-06-17 Formosa Laboratories, Inc. Novel Compounds and Preparation for Montelukast Sodium
CN102164897A (zh) * 2008-09-26 2011-08-24 株式会社Lg生命科学 制备孟鲁司特钠盐的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528254B2 (en) * 2006-02-27 2009-05-05 Chemagis Ltd. Process for preparing montelukast and salts thereof
US8115004B2 (en) * 2006-11-20 2012-02-14 Msn Laboratories Limited Process for pure montelukast sodium through pure intermediates as well as amine salts
KR100990046B1 (ko) * 2010-07-30 2010-10-26 동국제약 주식회사 신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100152453A1 (en) * 2006-10-24 2010-06-17 Formosa Laboratories, Inc. Novel Compounds and Preparation for Montelukast Sodium
CN101679268A (zh) * 2007-05-02 2010-03-24 波尔法玛制药工厂股份公司 制备1-(((1(r)-(3-(2-(7-氯-2-喹啉基)-乙烯基)苯基)-3-(2-(1-羟基-1-甲基乙基)苯基)丙基)硫烷基)甲基)环丙乙酸的钠盐的方法
CN101323589A (zh) * 2008-03-06 2008-12-17 台耀化学股份有限公司 新化合物及孟鲁司特钠的制备方法
WO2009117381A2 (en) * 2008-03-17 2009-09-24 Dr. Reddy's Laboratories Ltd. Preparation of montelukast and its salts
CN102164897A (zh) * 2008-09-26 2011-08-24 株式会社Lg生命科学 制备孟鲁司特钠盐的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAHMOUD M. AL OMARI等: "Effect of light and heat on the stability of montelukast in solution and in its solid state", 《JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS》 *
陈瀛，等: "孟鲁司特钠合成路线图解", 《中国医药工业杂志》 *

Also Published As

Publication number Publication date
WO2013058511A2 (ko) 2013-04-25
KR20130041664A (ko) 2013-04-25
JP2014530234A (ja) 2014-11-17
IN2014CN02765A (https=) 2015-07-03
WO2013058511A3 (ko) 2013-06-13

Similar Documents

Publication Publication Date Title
CN1144598C (zh) 利用氧化镁稳定的含ace抑制剂的组合物
CN100335046C (zh) 组合物
CN1547484A (zh) 无定形甲磺酸奈非那韦的药物剂型
CN1420766A (zh) 治疗充血性心力衰竭的部分脂肪酸氧化抑制剂
CN100344611C (zh) 4－硝基－2－[(4′－甲氧基)－苯氧基]－甲磺酰苯胺衍生物及其医药用途
CN1040143A (zh) 制备含喹啉羧酸的碱性制剂的方法
CN1509180A (zh) 用脂肪族聚胺治疗综合症x的方法
CN103889957A (zh) 制备高纯度孟鲁司特钠盐的方法
CN1147766A (zh) 治疗感染的药物
CN1671351A (zh) 具有化学预防活性的含nsaid的局部用药配方
CN1146413C (zh) 以对乙酰氨基酚为基础的注射用药物组合物
CN1327387A (zh) 羟丙甲基纤维素胶囊形式的药物制剂
CN111233878B (zh) 一种加兰他敏双羟萘酸盐及其制备方法
CN1638773A (zh) 以氨基苯磺酸衍生物作为活性成分的药物制剂
CN1511156A (zh) 碳青霉烯化合物
TW201343163A (zh) 含匹伐他汀（ｐｉｔａｖａｓｔａｔｉｎ）穩定配方的醫藥組合物
CN1822841A (zh) 抗冠状病毒剂
CN1794983A (zh) 奥兰西丁水溶液及其制备方法和消毒剂
CN1717238A (zh) 用于治疗眼紊乱和疾病的超氧化物歧化酶模拟物
CN111233877B (zh) 一种加兰他敏帕莫酸盐及其制备方法
CN1309125A (zh) 具抗癌活性的藤黄酸类化合物的复合物及其制备方法
JPH02172920A (ja) 抗潰瘍剤
CN1925861A (zh) 含有苄脒衍生物的组合物及苄脒衍生物的稳定化方法
CN1678584A (zh) 氨氯地平的有机酸盐
CN1391578A (zh) β－D－5－硫代木糖衍生物、其制备方法及医疗用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140625